Fiche publication
Date publication
novembre 2016
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Auteurs
Membres identifiés du Cancéropôle Est :
Dr POCHON Cécile
Tous les auteurs :
Visentin S, Auquier P, Bertrand Y, Baruchel A, Tabone MD, Pochon C, Jubert C, Poirée M, Gandemer V, Sirvent A, Bonneau J, Paillard C, Freycon C, Kanold J, Villes V, Berbis J, Oudin C, Galambrun C, Pellier I, Plat G, Chambost H, Leverger G, Dalle JH, Michel G
Lien Pubmed
Résumé
We compared the long-term impact of donor type (sibling donor [SD] versus matched unrelated donor [MUD] or umbilical cord blood [UCB]) on late side effects and quality of life (QoL) in childhood acute leukemia survivors treated with hematopoietic stem cell transplantation. We included 314 patients who underwent transplantation from 1997 to 2012 and were enrolled in the multicenter French Leucémie de l'Enfant et de L'Adolescent ("Leukemia in Children and Adolescents") cohort. More than one-third of the patients were adults at last visit; mean follow-up duration was 6.2 years. At least 1 late effect was observed in 284 of 314 patients (90.4%). The average number of adverse late effects was 2.1 ± .1, 2.4 ± .2, and 2.4 ± .2 after SD, MUD, and UCB transplantation, respectively. In a multivariate analysis, considering the SD group as the reference, we did not detect an impact of donor type for most sequelae, with the exception of increased risk of major growth failure after MUD transplantation (odds ratio [OR], 2.42) and elevated risk of osteonecrosis after UCB transplantation (OR, 4.15). The adults and children's parents reported comparable QoL among the 3 groups. Adult patient QoL scores were lower than age- and sex-matched French reference scores for almost all dimensions. We conclude that although these patients are heavily burdened by long-term complications, donor type had a very limited impact on their long-term health status and QoL.
Mots clés
Childhood leukemia, Cord blood transplantation, Hematopoietic stem cell transplantation, Late effects, Quality of life
Référence
Biol Blood Marrow Transplant. 2016 11;22(11):2003-2010